A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients
NCT00198094
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Subjects will include men and women over the age of eighteen;
- the ability to give written informed consent;
- current principal or co-principal psychiatric diagnosis of panic disorder with or without agoraphobia based on DSM-IV criteria (American Psychiatric Association, 1994);
- willing to use an effective means of contraception;
- free of psychoactive medications for at least 2 weeks prior to study enrollment;
- not actively be suicidal.
- actively suicidal;
- medical conditions for which either sertraline or alprazolam XR would be
contraindicated;
- recent six month history of substance or alcohol abuse;
- history or presence of psychotic or bipolar disorder;
- women who are pregnant or breastfeeding;
- history or presence of a seizure disorder or a known history of more than one
childhood febrile seizure;
- presence of a personality disorder severe enough to compromise the investigator's
ability to evaluate the efficacy and safety of the study medication;
- concomitant therapy with other psychotropic medication(s);
- clinically significant abnormality during physical examination, vital signs, EKG,
urine drug screen, or laboratory tests at the screen visit.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Tampa, Florida
- Indianapolis, Indiana
- Philadelphia, Pennsylvania
- Nagoya, Aichi
- Fukuoka-shi, Fukuoka
- Kitakyushu-shi, Fukuoka
- Kitakyusyu-shi, Fukuoka
- Sapporo-Shi, Hokkaido
- Sapporo, Hokkaido
- Higashiibaraki-gun, Ibaraki
- Fujisawa-city, Kanagawa
- Sagamihara-Shi, Kanagawa
- Yokohama-Shi, Kanagawa
- Yokohama, Kanagawa
- Kawaguchi-shi, Saitama
- Saitama city, Saitama
- Chiyoda-ku, Tokyo
- Kita-ku, Tokyo
- Minato-ku, Tokyo
- Musashino, Tokyo
- Nakano-Ku, Tokyo
- Nakanoku, Tokyo
- Setagaya-ku, Tokyo
- Shinjuku-ku, Tokyo
- Toshima-ku, Tokyo
- Nakano-ku, Yokohama
- Minato-ku,
| Descriptive Information | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients | |||||||||
| Official Title ICMJE | A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients | |||||||||
| Brief Summary | The primary objective for the study is to test the hypothesis that sertraline plus alprazolam XR will result in superior early stabilization of primary care PD patients versus sertraline/placebo over a 12-week treatment period. The secondary objectives of the study are a) to assess withdrawal symptoms during alprazolam XR taper (weeks 5-7 of the 12-week trial) and after discontinuation, b) to compare physical health outcomes, medical services utilization, and cost-effectiveness of the two study interventions across the 12-week treatment period and subsequent three month maintenance treatment with sertraline alone, and c) to assess whether early co-administration of sertraline/ alprazolam XR will result in greater maintenance of treatment response than sertraline/placebo over the three months following the 12 week acute treatment program. | |||||||||
| Detailed Description | Not Provided | |||||||||
| Study Type ICMJE | Interventional | |||||||||
| Study Phase ICMJE | Phase 4 | |||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||||||||
| Condition ICMJE | Panic Disorder | |||||||||
| Intervention ICMJE | Drug: Sertraline and Alprazolam XR | |||||||||
| Study Arms ICMJE | Not Provided | |||||||||
| Publications * | A randomized double-blind comparison of sertraline with early alprazolam XR Co-administration vs. sertraline/placebo for panic disorder. Goddard AW, Ball SG, Hastings AK, Shekhar A, Rickels K, Rynn M, Janavs J, Sheehan DV. BIOLOGICAL PSYCHIATRY 57 (8): 62S-62S 220 Suppl. S, APR 15 2005. IDS Number: 915VE ISSN: 0006-3223 | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||||||||
| Recruitment Information | ||||||||||
| Recruitment Status ICMJE | Completed | |||||||||
| Estimated Enrollment ICMJE | 150 | |||||||||
| Original Enrollment ICMJE | Same as current | |||||||||
| Actual Study Completion Date ICMJE | September 2007 | |||||||||
| Primary Completion Date | Not Provided | |||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||||||||
| Sex/Gender ICMJE |
| |||||||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||||||||
| Accepts Healthy Volunteers ICMJE | No | |||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||||||||
| Listed Location Countries ICMJE | United States | |||||||||
| Removed Location Countries | ||||||||||
| Administrative Information | ||||||||||
| NCT Number ICMJE | NCT00198094 | |||||||||
| Other Study ID Numbers ICMJE | 0311-34 IU 1003 | |||||||||
| Has Data Monitoring Committee | Yes | |||||||||
| U.S. FDA-regulated Product | Not Provided | |||||||||
| IPD Sharing Statement ICMJE | Not Provided | |||||||||
| Responsible Party | Not Provided | |||||||||
| Study Sponsor ICMJE | Indiana University School of Medicine | |||||||||
| Collaborators ICMJE |
| |||||||||
| Investigators ICMJE |
| |||||||||
| PRS Account | Indiana University | |||||||||
| Verification Date | October 2007 | |||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||||||||